Akari Therapeutics, Plc Accumulated Other Comprehensive Income
Akari Therapeutics, Plc (AKTX) had Accumulated Other Comprehensive Income of -$695.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$695.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$768.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$782.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.14M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$695.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$768.00K 10-Q · filed 2026-05-19 | |
| 2025-12-31 | -$782.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$1.14M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$1.11M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$773.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$738.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$926.00K 10-Q · filed 2024-11-19 | |
| 2024-06-30 | $141.93K 8-K · filed 2024-09-06 | -$749.00K 10-Q · filed 2024-08-19 |
| 2024-03-31 | -$761.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$1.04M 10-K · filed 2025-04-15 | |
| 2023-06-30 | -$825.88K 6-K · filed 2023-09-29 | |
| 2022-12-31 | $29.52K 8-K · filed 2024-09-06 | -$770.84K 20-F · filed 2023-05-01 |
| 2022-06-30 | -$621.56K 6-K · filed 2022-09-27 | |
| 2021-12-31 | -$540.97K 20-F · filed 2023-05-01 | |
| 2021-06-30 | -$420.09K 6-K · filed 2021-09-22 | |
| 2020-12-31 | -$648.07K 20-F · filed 2023-05-01 | |
| 2020-09-30 | -$621.30K 20-F · filed 2021-04-21 | |
| 2020-06-30 | -$617.62K 20-F · filed 2021-04-21 | |
| 2020-03-31 | -$571.59K 20-F · filed 2021-04-21 | |
| 2019-12-31 | -$348.86K 20-F · filed 2023-05-01 | |
| 2019-09-30 | -$402.09K 20-F · filed 2021-04-21 | |
| 2019-06-30 | -$405.37K 20-F · filed 2021-04-21 | |
| 2019-03-31 | -$245.26K 20-F · filed 2021-04-21 | |
| 2018-12-31 | -$352.43K 20-F · filed 2022-05-16 | |
| 2018-06-30 | -$230.63K 6-K · filed 2018-09-27 | |
| 2017-12-31 | -$236.25K 20-F · filed 2021-04-21 | |
| 2017-06-30 | -$373.83K 6-K · filed 2017-08-10 | |
| 2016-12-31 | -$280.10K 20-F · filed 2020-03-31 | |
| 2016-06-30 | -$191.87K 6-K · filed 2017-04-14 | |
| 2016-03-31 | -$36.46K 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $156.48K 20-F · filed 2019-04-23 | |
| 2015-09-30 | $197.09K 10-Q · filed 2015-11-23 | |
| 2014-12-31 | $46.08K 20-F · filed 2018-07-18 | |
| 2013-12-31 | -$33.36K 20-F · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |